N/A Completed N=66 Randomized Single-blind Treatment

Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome

KERATOCONJUNCTIVITIS SICCA · xerostomia · SICCA SYNDROME · PRIMARY SJOGREN SYNDROME

Source: ClinicalTrials.gov NCT02066896 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2017

Primary outcomePrimary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05

Summary

This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.

Outcome Measures

Outcome	Result	p-value
PRIMARY The Xerostomia Inventory	40.2; 39.3	0.05
SECONDARY Salivary Biomarker Analysis. Beta 2 Microglobulin.	1.10; 0.84	—
SECONDARY Salivary Flux Measurement	0.100; 0.100	—

Eligibility Criteria

Inclusion Criteria

Patients with primary Sjogren Syndrome according criteria american european 2002.
Salivary flux non stimulated < 0, 1 ml/min.

Exclusion Criteria

hepatitis B and/or C
radiotherapy in the glandular area (previous)
other connective diseases
thyroidopathy non compensated
GVHD graft-versus-host disease
HIV
Sarcoidosis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02066896). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.